Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Alzheimer's Disease

  Free Subscription

Articles published in Lancet Neurol

Retrieve available abstracts of 61 articles:
HTML format

Single Articles

    June 2020
  1. QUIROZ YT, Zetterberg H, Reiman EM, Chen Y, et al
    Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.
    Lancet Neurol. 2020;19:513-521.
    PubMed     Abstract available

    Major risk factors for Alzheimer's disease: age and genetics.
    Lancet Neurol. 2020;19:475-476.

    May 2020
  3. KARIKARI TK, Pascoal TA, Ashton NJ, Janelidze S, et al
    Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Lancet Neurol. 2020;19:422-433.
    PubMed     Abstract available

  4. MD JH
    Can we trust The End of Alzheimer's?
    Lancet Neurol. 2020;19:389-390.

    April 2020
  5. MCMANUS RM, Heneka MT
    T cells in Alzheimer's disease: space invaders.
    Lancet Neurol. 2020;19:285-287.

    February 2020
    A resurrection of aducanumab for Alzheimer's disease.
    Lancet Neurol. 2020;19:111-112.

    January 2020
  7. ANDREWS SJ, Fulton-Howard B, Goate A
    Interpretation of risk loci from genome-wide association studies of Alzheimer's disease.
    Lancet Neurol. 2020 Jan 24. pii: S1474-4422(19)30435.
    PubMed     Abstract available

    Preclinical Alzheimer's disease: a valid concept.
    Lancet Neurol. 2020;19:31.

    November 2019
  9. DING J, Davis-Plourde KL, Sedaghat S, Tully PJ, et al
    Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies.
    Lancet Neurol. 2019 Nov 6. pii: S1474-4422(19)30393.
    PubMed     Abstract available

    October 2019
  10. FRISONI GB, Ritchie C, Carrera E, Nilsson P, et al
    Re-aligning scientific and lay narratives of Alzheimer's disease.
    Lancet Neurol. 2019;18:918-919.

    August 2019
  11. LANE CA, Barnes J, Nicholas JM, Sudre CH, et al
    Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.
    Lancet Neurol. 2019 Aug 20. pii: S1474-4422(19)30228.
    PubMed     Abstract available

    July 2019
  12. SELKOE D
    beta-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
    Lancet Neurol. 2019;18:624-626.

    June 2019
  13. FRISONI GB, Alves IL, Barkhof F
    IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease.
    Lancet Neurol. 2019;18:519-520.

    February 2019
  14. ARRANZ AM, De Strooper B
    The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications.
    Lancet Neurol. 2019 Feb 19. pii: S1474-4422(18)30490.
    PubMed     Abstract available

  15. WALLACE LMK, Theou O, Godin J, Andrew MK, et al
    Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project.
    Lancet Neurol. 2019;18:177-184.
    PubMed     Abstract available

    January 2019
  16. IRWIN MR, Vitiello MV
    Implications of sleep disturbance and inflammation for Alzheimer's disease dementia.
    Lancet Neurol. 2019 Jan 17. pii: S1474-4422(18)30450.
    PubMed     Abstract available

    December 2018
    Will Europe be ready for the treatment of Alzheimer's disease?
    Lancet Neurol. 2018;17:1025.

    November 2018

  18. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
    Lancet Neurol. 2018 Nov 26. pii: S1474-4422(18)30403.
    PubMed     Abstract available

    October 2018
  19. BALIN BJ, Hudson AP
    Herpes viruses and Alzheimer's disease: new evidence in the debate.
    Lancet Neurol. 2018;17:839-841.

    August 2018
  20. FORTEA J, Carmona-Iragui M, Benejam B, Fernandez S, et al
    Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30285.
    PubMed     Abstract available

  21. RAFII MS
    Diagnostic biomarkers of Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30293.

  22. CARMONA S, Zahs K, Wu E, Dakin K, et al
    The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders.
    Lancet Neurol. 2018;17:721-730.
    PubMed     Abstract available

  23. Jo Barnes.
    Lancet Neurol. 2018;17:667.

    July 2018
  24. MORGAN J
    No one knows what tomorrow might bring.
    Lancet Neurol. 2018;17:585.

    June 2018
  25. KNUDSEN K, Fedorova TD, Hansen AK, Sommerauer M, et al
    In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study.
    Lancet Neurol. 2018 Jun 1. pii: S1474-4422(18)30162.
    PubMed     Abstract available

    May 2018
  26. DUFOUIL C, Glymour MM
    Prediction to prevention in Alzheimer's disease and dementia.
    Lancet Neurol. 2018;17:388-389.

  27. ZIMMERMANN JF, Butler CR
    Accelerated long-term forgetting in asymptomatic APOE epsilon4 carriers.
    Lancet Neurol. 2018;17:394-395.

    April 2018
  28. FRISONI GB, Jessen F
    One step towards dementia prevention.
    Lancet Neurol. 2018;17:294-295.

    March 2018
  29. VAN DER LEE SJ, Wolters FJ, Ikram MK, Hofman A, et al
    The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study.
    Lancet Neurol. 2018 Mar 16. pii: S1474-4422(18)30053.
    PubMed     Abstract available

  30. BALLARD C, Banister C, Khan Z, Cummings J, et al
    Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Lancet Neurol. 2018;17:213-222.
    PubMed     Abstract available

    Pimavanserin for patients with Alzheimer's disease psychosis.
    Lancet Neurol. 2018;17:194-195.

    February 2018
  32. DUBOIS B, Epelbaum S, Nyasse F, Bakardjian H, et al
    Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Lancet Neurol. 2018 Feb 27. pii: S1474-4422(18)30029.
    PubMed     Abstract available

  33. WESTON PSJ, Nicholas JM, Henley SMD, Liang Y, et al
    Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2018;17:123-132.
    PubMed     Abstract available

    Long-term forgetting in preclinical Alzheimer's disease.
    Lancet Neurol. 2018;17:104-105.

    January 2018
  35. GORDON BA, Blazey TM, Su Y, Hari-Raj A, et al
    Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30028.
    PubMed     Abstract available

  36. TIJMS BM, Visser PJ
    Capturing the Alzheimer's disease pathological cascade.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30043.

  37. AUGUSTIN K, Khabbush A, Williams S, Eaton S, et al
    Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders.
    Lancet Neurol. 2018;17:84-93.
    PubMed     Abstract available

    December 2017
    Alzheimer's disease: evolution of research diagnostic criteria.
    Lancet Neurol. 2017;16:945.

    November 2017
    Pathology and hippocampal atrophy in Alzheimer's disease.
    Lancet Neurol. 2017;16:862-864.

    October 2017
  40. SOININEN H, Solomon A, Visser PJ, Hendrix SB, et al
    24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30332.
    PubMed     Abstract available

    Targeting prodromal Alzheimer's disease: too late for prevention?
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30372.

    September 2017
  42. JOSEPHS KA, Dickson DW, Tosakulwong N, Weigand SD, et al
    Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.
    Lancet Neurol. 2017 Sep 11. pii: S1474-4422(17)30284.
    PubMed     Abstract available

  43. DROUIN E, Drouin G
    The first report of Alzheimer's disease.
    Lancet Neurol. 2017;16:687.

    August 2017
  44. FRISONI GB, Boccardi M, Barkhof F, Blennow K, et al
    Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
    Lancet Neurol. 2017;16:661-676.
    PubMed     Abstract available

  45. COLEY N, Andrieu S
    Lessons from the Multidomain Alzheimer Preventive Trial - Authors' reply.
    Lancet Neurol. 2017;16:586.

  46. YASSINE HN, Schneider LS
    Lessons from the Multidomain Alzheimer Preventive Trial.
    Lancet Neurol. 2017;16:585-586.

  47. ESCOTT-PRICE V, Jones L
    Genomic profiling and diagnostic biomarkers in Alzheimer's disease.
    Lancet Neurol. 2017;16:582-583.

  48. ISAAC MT, Vamvakas S, Isaac MB
    Diagnostic biomarkers for Alzheimer's disease: a regulatory view.
    Lancet Neurol. 2017;16:580-581.

    June 2017
  49. KIRBY T
    Eric Reiman: aiming to prevent Alzheimer's disease.
    Lancet Neurol. 2017 Jun 30. pii: S1474-4422(17)30216.

    May 2017
  50. HARDY J
    Membrane damage is at the core of Alzheimer's disease.
    Lancet Neurol. 2017;16:342.

    April 2017
  51. VOSSEL KA, Tartaglia MC, Nygaard HB, Zeman AZ, et al
    Epileptic activity in Alzheimer's disease: causes and clinical relevance.
    Lancet Neurol. 2017;16:311-322.
    PubMed     Abstract available

    February 2017
    Solanezumab: too late in mild Alzheimer's disease?
    Lancet Neurol. 2017;16:97.

    January 2017
    Alzheimer's disease and other dementias: update on research.
    Lancet Neurol. 2017;16:4-5.

  54. ATTEMS J
    Alzheimer's disease pathology in synucleinopathies.
    Lancet Neurol. 2017;16:22-23.

  55. IRWIN DJ, Grossman M, Weintraub D, Hurtig HI, et al
    Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Lancet Neurol. 2017;16:55-65.
    PubMed     Abstract available

    December 2016
  56. PANZA F, Logroscino G
    Anti-tau vaccine in Alzheimer's disease: a tentative step.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30340.

  57. NOVAK P, Schmidt R, Kontsekova E, Zilka N, et al
    Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30331.
    PubMed     Abstract available

    October 2016
  58. RYAN NS, Nicholas JM, Weston PS, Liang Y, et al
    Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30193.
    PubMed     Abstract available

    Clinical heterogeneity in familial Alzheimer's disease.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30275.

  60. TANG M, Ryman DC, McDade E, Jasielec MS, et al
    Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30229.
    PubMed     Abstract available

    August 2016
  61. MORGAN J
    An orange and Alzheimer's disease?
    Lancet Neurol. 2016;15:911.

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.